Send to

Choose Destination
Expert Rev Vaccines. 2004 Dec;3(6):655-63.

Vaccination with Theratope (STn-KLH) as treatment for breast cancer.

Author information

University of Washington School of Medicine, Department of Medicine, and Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. PO Box 19024, D5-390, Seattle, WA 98109-1024, USA.


Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated antigens in the laboratory. However, few clinical studies with cancer vaccines have demonstrated convincing clinical responses. Sialyl-Tn is a carbohydrate associated with MUC1. It is a unique tumor-associated antigen, present on many adenocarcinomas including breast, ovarian, colorectal, gastric and pancreatic. Consequently, Sialyl-TN is an ideal candidate for boosting the patient's immune system specifically against a unique tumor-associated antigen. The cancer vaccine Theratope was developed by Biomira, Inc. using a synthetic Sialyl-Tn antigen that emulates the unique carbohydrate on human cancer. Clinical trials have predominantly been carried out in breast cancer patients and these trials are outlined in this profile.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center